270 related articles for article (PubMed ID: 29496465)
21. The role of interleukin 5 in asthma.
Varricchi G; Canonica GW
Expert Rev Clin Immunol; 2016 Sep; 12(9):903-5. PubMed ID: 27450970
[No Abstract] [Full Text] [Related]
22. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.
Assa'ad AH; Gupta SK; Collins MH; Thomson M; Heath AT; Smith DA; Perschy TL; Jurgensen CH; Ortega HG; Aceves SS
Gastroenterology; 2011 Nov; 141(5):1593-604. PubMed ID: 21835135
[TBL] [Abstract][Full Text] [Related]
23. Systemic cytokine storm in severe eosinophilic dermatitis.
Singanayagam A; Lamb L; Makinde JE; Teo I; Shaunak S
QJM; 2015 Nov; 108(11):907-8. PubMed ID: 25725251
[No Abstract] [Full Text] [Related]
24. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
25. Reslizumab (Cinqair) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
[No Abstract] [Full Text] [Related]
26. Inhibition of interleukin-5 for the treatment of eosinophilic diseases.
Corren J
Discov Med; 2012 Apr; 13(71):305-12. PubMed ID: 22541618
[TBL] [Abstract][Full Text] [Related]
27. Anti-IL5 decreases the number of eosinophils but not the severity of dermatitis in Sharpin-deficient mice.
Renninger ML; Seymour RE; Whiteley LO; Sundberg JP; Hogenesch H
Exp Dermatol; 2010 Mar; 19(3):252-8. PubMed ID: 19650867
[TBL] [Abstract][Full Text] [Related]
28. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial.
Spergel JM; Rothenberg ME; Collins MH; Furuta GT; Markowitz JE; Fuchs G; O'Gorman MA; Abonia JP; Young J; Henkel T; Wilkins HJ; Liacouras CA
J Allergy Clin Immunol; 2012 Feb; 129(2):456-63, 463.e1-3. PubMed ID: 22206777
[TBL] [Abstract][Full Text] [Related]
29. Hypereosinophilic syndrome presenting acutely with neurologic signs.
Brunet BA; Sugg RM; Stewart P
Ann Allergy Asthma Immunol; 2018 May; 120(5):461-464. PubMed ID: 29501486
[No Abstract] [Full Text] [Related]
30. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Olivieri B; Tinazzi E; Caminati M; Lunardi C
Immunol Allergy Clin North Am; 2020 Nov; 40(4):649-665. PubMed ID: 33012326
[TBL] [Abstract][Full Text] [Related]
31. Benralizumab Completely Depletes Gastrointestinal Tissue Eosinophils and Improves Symptoms in Eosinophilic Gastrointestinal Disease.
Kuang FL; De Melo MS; Makiya M; Kumar S; Brown T; Wetzler L; Ware JM; Khoury P; Collins MH; Quezado M; Pittaluga S; Klion AD
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1598-1605.e2. PubMed ID: 35283330
[TBL] [Abstract][Full Text] [Related]
32. Hypereosinophilic syndrome: approach to treatment in the era of precision medicine.
Klion A
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):326-331. PubMed ID: 30504328
[TBL] [Abstract][Full Text] [Related]
33. Eosinophilic disorders in children.
Wagelie-Steffen A; Aceves SS
Curr Allergy Asthma Rep; 2006 Nov; 6(6):475-82. PubMed ID: 17026874
[TBL] [Abstract][Full Text] [Related]
34. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.
Amini-Vaughan ZJ; Martinez-Moczygemba M; Huston DP
Curr Allergy Asthma Rep; 2012 Oct; 12(5):402-12. PubMed ID: 22875242
[TBL] [Abstract][Full Text] [Related]
36. Eosinophilic dermatoses.
Peckruhn M; Elsner P; Tittelbach J
J Dtsch Dermatol Ges; 2019 Oct; 17(10):1039-1051. PubMed ID: 31562692
[TBL] [Abstract][Full Text] [Related]
37. Idiopathic Hypereosinophilic Syndrome With Cutaneous Manifestations and Flame Figures: A Spectrum of Eosinophilic Dermatoses Whose Features Overlap With Wells' Syndrome.
Smith SM; Kiracofe EA; Clark LN; Gru AA
Am J Dermatopathol; 2015 Dec; 37(12):910-4. PubMed ID: 25839890
[TBL] [Abstract][Full Text] [Related]
38. Group 2 innate lymphocytes (ILC2) are enriched in active eosinophilic esophagitis.
Doherty TA; Baum R; Newbury RO; Yang T; Dohil R; Aquino M; Doshi A; Walford HH; Kurten RC; Broide DH; Aceves S
J Allergy Clin Immunol; 2015 Sep; 136(3):792-794.e3. PubMed ID: 26233928
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.
Kuang FL; Fay MP; Ware J; Wetzler L; Holland-Thomas N; Brown T; Ortega H; Steinfeld J; Khoury P; Klion AD
J Allergy Clin Immunol Pract; 2018; 6(5):1518-1527.e5. PubMed ID: 29751154
[TBL] [Abstract][Full Text] [Related]
40. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
